Paya Carlos V 4

4 · Vaxcyte, Inc. · Filed Jun 16, 2026

AI-generated summary of this filing

Updated Jun 16, 2026

Vaxcyte (PCVX) Director Carlos V. Paya Receives Award

What Happened

Carlos V. Paya, a director of Vaxcyte, received awards on 2026-06-15 totaling 13,654 share-equivalents: 2,265 restricted stock units (RSUs) and 11,389 derivative units (awarded at $0.00). The awards were reported on a Form 4 filed 2026-06-16.
These are grants (no cash paid). The RSUs and the derivative award vest over time and are not immediate open-market purchases or sales.

Key Details

Transaction date: 2026-06-15; Filing date (Accession): 2026-06-16 (appears timely).
Awards: 2,265 RSUs @ $0.00; 11,389 derivative units @ $0.00; total 13,654 units.
Vesting: Both awards fully vest on the earlier of June 15, 2027 or the day before the next annual meeting, subject to acceleration and the reporting person's continued service.
Deferral: The RSUs are deferred under the issuer’s Nonqualified RSU Deferral Program for non-employee directors — delivery is deferred until separation from service or a qualifying change in control.
Derivative specifics: The 11,389 units are subject to monthly vesting (per footnote) and fully vest on the same schedule noted above.
Shares owned after transaction: Not specified in this filing.

Context

This is a typical equity compensation grant for a non-employee director, not an open-market purchase or sale. Such awards are common for director compensation and do not by themselves indicate buy/sell directional intent.
Because delivery of the RSUs is deferred and vesting is time-based, the awards represent future potential ownership contingent on continued service (or a change in control).

Form 4

Period: 2026-06-15

Director

Transactions

Award
Common Stock
[F1]
2026-06-15+2,265→ 6,856 total
Award
Stock Option (right to buy)
[F2]
2026-06-15+11,389→ 11,389 total
Exercise: $49.56Exp: 2036-06-15→ Common Stock (11,389 underlying)

Holdings

Footnotes (2)

[F1]Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control.
[F2]The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Signature

Carlos V. Paya, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-06-16

1 file